Estimating probable aplication ofcaragenans for recipient-oriented delivery of anticancer drugs
Abstract
The authors estimate binding ability of ι-carrageenan
with respect to anti-tumor drugs - cyclophosphamide and
dacarbazine. The carrageenan selectively bind and retain molecules
of dacarbazine in the polysaccharidic gel medium structure
due to chemical adsorption processes that can be used to create
new all-inclusive drugs for recipient-oriented delivery of drug
substances with controlled release of an active compound.
with respect to anti-tumor drugs - cyclophosphamide and
dacarbazine. The carrageenan selectively bind and retain molecules
of dacarbazine in the polysaccharidic gel medium structure
due to chemical adsorption processes that can be used to create
new all-inclusive drugs for recipient-oriented delivery of drug
substances with controlled release of an active compound.
About the Authors
М. Хотимченко
Владивостокский государственный медицинский университет
Russian Federation
Russian Federation
О. Шокур
Дальневосточный государственный медицинский университет
Russian Federation
Russian Federation
Н. Ламаш
Институт биологии моря имени А.В. Жирмунского ДВО РАН
Russian Federation
Russian Federation
M. Yu. Khotimchenko
Vladivostok State Medical University
Russian Federation
Russian Federation
O. A. Shokur
Far-Eastern State Medical University
Russian Federation
Russian Federation
N. E. Lamash
Institute
of Marine Biology named after A.V. Zhirmundsky, FEB
RAS
Russian Federation
Russian Federation
References
1. Brant D., Buliga G. Chemical Structure and macromolecular conformation of polysaccharides in the aqueous environment // Biotechnology of marine polysaccharides / ed. Colwell E. Washington- New York-London, 1985. P. 29-73.
2. Chapman V.J., Chapman D.J. Seaweeds and their uses. London- New York: Chapman and Hall, 1980. 334 p.
3. Cicala C., Morello S., Alfieri A. et al. Haemostatic imbalance following carrageenan-induced rat paw oedema // Eur. J. Pharmacol. 2007. Vol. 577. P. 156-161.
4. Coimbra M., Kuijpers S.A., van Seters S.P. et al. Targeted delivery of anti-inflammatory agents to tumors // Curr. Pharm. Des. 2009. Vol. 15. P. 1825-1843.
5. Mohamadnia Z., Zohuriaan-Mehr M.J., Kabiri K. et al. pHSensitive IPN Hydrogel Beads of Carrageenan-Alginate for Controlled Drug Delivery // J. Bioact. Compatible Polymers. 2007. Vol. 22. P. 342-356.
6. Panlasigui L.N., Baello O.Q., Dimatangal J.M., Dumelod B.D. Blood cholesterol and lipid-lowering effects of carrageenan on human volunteers // Asia Pac. J. Clin. Nutr. 2003. Vol. 12. P. 209-214.
7. Santo V.E., Frias A.M., Carida M., et al. Carrageenan-Based Hydrogels for the Controlled Delivery of PDGF-BB in Bone Tissue Engineering Applications // Biomacromolecules. 2009. Vol. 10. P. 1392-1401
8. Volesky B. Sorption and biosorption. Quebec: BV-Sorbex Inc., St. Lambert, 2004. 316 p.
9. Volesky B. Naja G. Biosorption technology: Starting up an enterprise // Int. J. Technology Transfer & Commercialization. 2007. Vol. 6. P. 196-211.
10. Wagner A.D., Moehler M. Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era // Curr. Opin. Oncol. 2009. Vol. 21. P. 381-385.
11. Yermak I.M., Khotimchenko Y.S. Chemical properties, biological activities and applications of carrageenans from red algae // Recent Advan. Mar. Biotechnol. 2003. Vol. 9. P. 207-255.
12. Yoshikawa Y., Hirayasu H., Tsuzuki S., Fushiki T. Carrageenan inhibits granzyme A-induced detachment of and interleukin- 8 release from alveolar epithelial A549 cells // Cytotechnology. 2008. Vol. 58. P. 63-67.
13. Zhou G., Sheng W., Yao W., Wang C. Effect of low molecular lambda-carrageenan from Chondrus ocellatus on antitumor H‑22 activity of 5-Fu // Pharmacol. Res. 2006. Vol. 53. P. 129-134.
Review
For citations:
, , , Khotimchenko M.Yu., Shokur O.A., Lamash N.E. Estimating probable aplication ofcaragenans for recipient-oriented delivery of anticancer drugs. Pacific Medical Journal. 2010;(2):59-62. (In Russ.)
Views:
193
Email this article 